Antagonistic molecular interactions of photosynthetic pigments with molecular disease targets: A new approach to treat AD and ALS

Journal of Receptors and Signal Transduction

Volumn 36, Issue 1, 2016, Pages 67-71

  Krishnaraj, R Navanietha ^a   Kumari, S S Sreeja ^b   Mukhopadhyay, Sudit Sekhar ^a  

^a NATIONAL INSTITUTE OF TECHNOLOGY   (India)

^b CENTRAL ELECTROCHEMICAL RESEARCH INSTITUTE   (India)

Author keywords

Alzheimer's disease; amyotrophic lateral sclerosis; binding energy; docking; pigments

Indexed keywords

BETA CAROTENE; CHLOROPHYLL A; CHLOROPHYLL B; NEUROTROPHIN RECEPTOR P75; PHYCOCYANIN; PHYCOERYTHRIN; PIGMENT; CHLOROPHYLL; EPHRIN RECEPTOR A4; HISTONE DEACETYLASE;

ALGORITHM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTICLE; BINDING AFFINITY; DRUG TARGETING; HUMAN; MOLECULAR DOCKING; MOLECULAR INTERACTION; RECEPTOR BINDING ASSAY; TREATMENT INDICATION; CHEMISTRY; METABOLISM; MOLECULAR MODEL; PROTEIN CONFORMATION;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BETA CAROTENE; CHLOROPHYLL; HISTONE DEACETYLASES; HUMANS; MODELS, MOLECULAR; PHYCOCYANIN; PHYCOERYTHRIN; PROTEIN CONFORMATION; RECEPTOR, EPHA4;

EID: 84955147943     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2015.1024851     Document Type: Article

References (26)

1. Giordano M, Dominguez LJ, Vitrano T, et al. Combination of intensive cognitive rehabilitation and donepezil therapy in Alzheimer's disease (AD). Archiv Gerontol Geriatr 2010;51:245-9.
2. Speck-Planche A, Kleandrova VV, Luan F, Cordeiro MN. Multitarget inhibitors for proteins associated with Alzheimer. In silico discovery using fragment-based descriptors. Curr Alzheimer Res 2013;10:117-24.
3. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000;1:120-9.
4. Shimohama S. Apoptosis in Alzheimer's disease-an update. Apoptosis 2000;5:9-16.
5. Toiber D, Berson A, Greenberg D, et al. N-acetylcholinesterase-induced apoptosis in Alzheimer's disease. PLoS One 2008. doi:10.1371/journal.pone.0003108.
6. Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener Dis 2005;2:147-59.
7. Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 1997;69:2064-74.
8. Howland DS, Liu J, She Y, et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 2002;99:1604-9.
9. Williamson TL, Cleveland DW. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat Neurosci 1999;2:50-6.
10. Manfredi G, Xu Z. Mitochondrial dysfunction and its role in motor neuron degeneration in ALS. Mitochondrion 2005;5:77-87.
11. Estévez AG, Crow JP, Sampson JB, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999;286:2498-500.
12. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;CD001447. doi:10.1002/14651858.
13. Coulson EJ, May LM, Osborne SL, et al. p75 neurotrophin receptor mediates neuronal cell death by activating GIRK channels through phosphatidylinositol 4,5-bisphosphate. J Neurosci 2008;28:315-24.
14. Kalb R. The protean actions of neurotrophins and their receptors on the life and death of neurons. Trends Neurosci 2005;28:5-11.
15. Sathasivam S, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis - what is the evidence? Lancet Neurol 2005;4:500-9
16. Van Hoecke A, Schoonaert L, Lemmens R, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 2012;18:1418-22.
17. Fu AK, Hung KW, Huang H, et al. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proc Natl Acad Sci USA 2014;111:9959-64.
18. Schmalbach S, Petri S. Histone deacetylation and motor neuron degeneration. CNS Neurol Disord Drug Targets 2010;9:279-84.
19. Echaniz-Laguna A, Bousiges O, Loeffler JP, Boutillier AL. Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases. Curr Med Chem 2008;15:1263-673.
20. Yoo YE, Ko CP. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2011;231:147-59.
21. Petri S, Kiaei M, Kipiani K, et al. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2006;22:40-9.
22. Xu K, Dai XL, Huang HC, Jiang ZF. Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid Med Cell Longev 2011;2011:143269.
23. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008;7:854-68.
24. Janssen C, Schmalbach S, Boeselt S, et al. Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2010;69:573-81.
25. Del Signore SJ, Amante DJ, Kim J, et al. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler 2009;10:85-94.
26. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;3:455-61.